Intracoronary Human Wharton's Jelly- Derived Mesenchymal Stem Cells (WJ-MSCs) Transfer in Patients With Acute Myocardial Infarction (AMI)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 160 participants.
Also called NCT01291329
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 160 participants
- Sponsor
- Registry
-
NCT01291329
-
- Other papers using this trial's data
- Intracoronary infusion of Wharton's jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT01291329. Randomized; quadruple masking; primary purpose treatment. Start 2011-02 (registry gives no type); primary completion 2012-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Intracoronary Human Wharton's Jelly- Derived Mesenchymal Stem Cells (WJ-MSCs) Transfer in Patients With Acute Myocardial Infarction (AMI)
- Acronym
- WJ-MSC-AMI
- Condition
- ST-Elevation Myocardial Infarction
- Intervention (Genetic)
- intracoronary human umbilical WJ-MSC transfer
- Lead sponsor
- Navy General Hospital, Beijing
- Collaborator
- Chinese PLA General Hospital
- Collaborator
- General Hospital of Chinese Armed Police Forces
- Collaborator
- First People's Hospital of Foshan
Record details
- Record id
cardio:ct-nct01291329- Content hash
cacc3c5edcd965a0a38f513b459ba44c356115edd7b088bea7adc6a420bcb4c1